PYLERA
LOE Approachingbismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
NDAORALCAPSULE
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYLERA is a fixed-dose oral capsule combining bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride for H. pylori eradication therapy. This triple-agent combination works synergistically to target bacterial cell walls and inhibit protein synthesis. It is indicated as part of a multi-drug regimen for patients with H. pylori infection and associated peptic ulcer disease.
$0.002BPart D
LOE ApproachingWith LOE approaching and modest Part D spending of $2M on 2,120 claims, the PYLERA brand team is likely in managed decline mode with reduced headcount and focus on transition planning.
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PYLERA presents limited and declining career opportunities as a mature, LOE-approaching product with no linked job openings. Roles on this product focus on defensive commercialization, compliance, and transition planning rather than growth initiatives or innovation.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.